Replies to post #190889 on Biotech Values

[DewDiligence]

ABBV—Venetoclax +Rituxan produced 84% RR in second-line CLL:

http://finance.yahoo.com/news/phase-1b-study-investigational-treatment-063000315.html

AbbVie…announced updated results of a Phase 1b study that showed patients with relapsed/refractory chronic lymphocytic leukemia (CLL) taking venetoclax, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab, had an overall response rate (ORR) of 84 percent (n=41/49).

Additionally, six patients stopped venetoclax after achieving either a complete response (CR) or CR with incomplete marrow recovery (CRi). Three patients maintained a response after a median of 12 months (0-21). These data were detailed in an oral presentation at the 20th Congress of the European Hematology Association (EHA), June 11-15, in Vienna.

Venetoclax (f/k/a ABT-199) has BTD in second-line CLL with 17p-deletion (#msg-113394081).